EE9900147A - Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena - Google Patents

Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena

Info

Publication number
EE9900147A
EE9900147A EEP199900147A EE9900147A EE9900147A EE 9900147 A EE9900147 A EE 9900147A EE P199900147 A EEP199900147 A EE P199900147A EE 9900147 A EE9900147 A EE 9900147A EE 9900147 A EE9900147 A EE 9900147A
Authority
EE
Estonia
Prior art keywords
oxadiazoles
pharmaceuticals
preparation
methods
Prior art date
Application number
EEP199900147A
Other languages
English (en)
Estonian (et)
Inventor
Brenner Michael
Maier Roland
Wienrich Marion
Weiser Thomas
Palluk Rainer
Bechtel Wolf-Dietrich
Sagrada Angelo
Ensinger Helmut
Pschorn Uwe
Cesana Raffaele
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of EE9900147A publication Critical patent/EE9900147A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP199900147A 1996-10-18 1997-10-15 Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena EE9900147A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19643037A DE19643037A1 (de) 1996-10-18 1996-10-18 Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
PCT/EP1997/005693 WO1998017652A1 (fr) 1996-10-18 1997-10-15 Oxadiazoles, procedes permettant de les preparer et leur utilisation comme medicaments

Publications (1)

Publication Number Publication Date
EE9900147A true EE9900147A (et) 1999-12-15

Family

ID=7809114

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900147A EE9900147A (et) 1996-10-18 1997-10-15 Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena

Country Status (32)

Country Link
US (1) US6277872B1 (fr)
EP (1) EP0934288B1 (fr)
JP (1) JP3333523B2 (fr)
KR (1) KR20000049253A (fr)
CN (1) CN1086698C (fr)
AR (1) AR008496A1 (fr)
AT (1) ATE315034T1 (fr)
AU (1) AU737552B2 (fr)
BG (1) BG103251A (fr)
BR (1) BR9714354A (fr)
CA (1) CA2268954C (fr)
CO (1) CO4920253A1 (fr)
CZ (1) CZ138099A3 (fr)
DE (2) DE19643037A1 (fr)
EE (1) EE9900147A (fr)
ES (1) ES2256880T3 (fr)
HK (1) HK1020956A1 (fr)
HR (1) HRP970553A2 (fr)
HU (1) HUP0001652A3 (fr)
ID (1) ID18613A (fr)
IL (1) IL129315A0 (fr)
NO (1) NO312512B1 (fr)
NZ (1) NZ335598A (fr)
PE (1) PE11199A1 (fr)
PL (1) PL332432A1 (fr)
RU (1) RU2182905C2 (fr)
SK (1) SK49999A3 (fr)
TR (1) TR199900848T2 (fr)
TW (1) TW413678B (fr)
WO (1) WO1998017652A1 (fr)
YU (1) YU40997A (fr)
ZA (1) ZA979220B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1300055B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
IT1300056B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
US6825192B1 (en) 1999-02-15 2004-11-30 Eisai Co., Ltd. Heterodiazinone derivatives
ATE257827T1 (de) 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UA75871C2 (en) * 1999-08-19 2006-06-15 Nps Pharma Inc 1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors
EP1582519A3 (fr) * 1999-08-19 2005-12-21 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisation comme antagonistes des recepteurs glutamiques metabotropes
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
KR100770327B1 (ko) * 2000-09-18 2007-10-25 에자이 알앤드디 매니지먼트 가부시키가이샤 피리다지논 및 트리아지논 화합물류 및 그들의 의약 용도
SI1379525T1 (sl) * 2001-02-21 2007-12-31 Astrazeneca Ab Heteropoliciklične spojine in njihova uporaba kot antagonisti metabotropnih glutamatnih receptorjev
ATE396186T1 (de) * 2001-10-04 2008-06-15 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP2006501312A (ja) 2002-08-23 2006-01-12 ライジェル ファーマシューティカルズ, インコーポレイテッド Hcv感染を治療または予防するのに有用なピリジル置換複素環
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
EP1620412A2 (fr) 2003-05-02 2006-02-01 Rigel Pharmaceuticals, Inc. Composes heterocycliques et certains de leurs hydro-isomeres
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
WO2005049065A2 (fr) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Combinaisons efficaces d'un point de vue synergique de composes dihaloacetamide et d'interferon ou de ribavirine contre les infections par le virus de l'hepatite c (vhc)
CN1898235A (zh) 2003-12-24 2007-01-17 普罗西迪恩有限公司 作为gpcr受体激动剂的杂环衍生物
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
CA2603959A1 (fr) * 2005-04-08 2006-10-19 Eisai R & D Management Co., Ltd. Agent pour traiter un mouvement involontaire
CN101203498A (zh) 2005-05-02 2008-06-18 里格尔药品股份有限公司 包括可代谢部分的杂环抗病毒化合物及其用途
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
BRPI0720043A2 (pt) * 2006-12-15 2014-01-07 Abbott Lab Composto oxadiazol
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
AU2008306886B2 (en) * 2007-10-04 2014-01-16 Merck Serono S.A. Oxadiazole diaryl compounds
WO2009082398A1 (fr) * 2007-12-21 2009-07-02 University Of Notre Dame Du Lac Composés antibactériens et leurs procédés d'utilisation
EP2307381B1 (fr) 2008-06-09 2021-01-13 Ludwig-Maximilians-Universität München Nouveaux médicaments pour l'inhibition de l'agrégation des protéines impliquées dans des maladies associées à l'agrégation des protéines et/ou des maladies neurodégénératives
WO2011047129A1 (fr) * 2009-10-15 2011-04-21 Southern Research Institute Traitement de maladies neurodégénératives, cause d'amélioration de la mémoire et analyse pour évaluer des composés associés
US9328078B2 (en) * 2012-08-24 2016-05-03 Treventis Corporation Benzofurazan anti-amyloid compounds and methods
WO2015131021A2 (fr) 2014-02-27 2015-09-03 Treventis Corporation Composés anti-protéine amyloïde contenant du benzofurazane
WO2015163478A1 (fr) 2014-04-24 2015-10-29 住友化学株式会社 Composé diaryl-azole
CA2962431A1 (fr) * 2014-09-25 2016-03-31 University Of Notre Dame Du Lac Antibiotiques autres que les beta-lactamines
CN107286174B (zh) * 2016-04-11 2020-08-18 上海勋和医药科技有限公司 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用
WO2018049404A1 (fr) 2016-09-12 2018-03-15 University Of Notre Dame Du Lac Composés pour le traitement d'une infection par clostridium difficile
JP7283699B2 (ja) 2017-05-12 2023-05-30 マックス-プランク-ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル-ヘテロ環-フェニル誘導体
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
EP4403184A1 (fr) 2021-09-15 2024-07-24 University of The Ryukyus Composition pharmaceutique destinée à être mise en ?uvre dans le traitement soit du déclin des fonctions cognitives, soit de la surcharge pondérale ou de l'obésité
WO2023042888A1 (fr) 2021-09-15 2023-03-23 国立大学法人 琉球大学 Composition pharmaceutique destinée à être mise en œuvre dans le traitement soit du déclin des fonctions cognitives, soit de la surcharge pondérale ou de l'obésité
EP4173485A1 (fr) 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composés inhibant l'agrégation de protéine pour la lutte contre les maladies des plantes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
JPS52272A (en) * 1975-10-17 1977-01-05 Takeda Chem Ind Ltd Process for preparing 1,2,4-oxadiazole derivatives
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な1,2,4−オキサジアゾ−ル誘導体
US4871753A (en) * 1986-12-12 1989-10-03 Ciba-Geigy Corporation 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
JPH02250873A (ja) * 1989-03-24 1990-10-08 Mitsubishi Petrochem Co Ltd 1,2,4―オキサジアゾール誘導体及びそれを有効成分とする除草剤
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DK443489D0 (da) * 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−b酵素阻害活性を有する1,2,4−オキサジアゾール誘導体及びその製造法
US5492919A (en) * 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
DE4401107A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 3-Aryl-alkenyl-1,2,4-oxadiazol-Derivate
DE19528189A1 (de) * 1995-08-01 1997-02-06 Basf Ag Benzolderivate mit einem heterocyclischen Rest

Also Published As

Publication number Publication date
TW413678B (en) 2000-12-01
CN1233245A (zh) 1999-10-27
JP3333523B2 (ja) 2002-10-15
TR199900848T2 (xx) 1999-06-21
AU4867697A (en) 1998-05-15
CA2268954A1 (fr) 1998-04-30
HK1020956A1 (en) 2000-05-26
WO1998017652A1 (fr) 1998-04-30
ES2256880T3 (es) 2006-07-16
CO4920253A1 (es) 2000-05-29
PE11199A1 (es) 1999-03-03
NO991815L (no) 1999-04-16
KR20000049253A (ko) 2000-07-25
RU2182905C2 (ru) 2002-05-27
NO312512B1 (no) 2002-05-21
IL129315A0 (en) 2000-02-17
HUP0001652A2 (hu) 2001-01-29
EP0934288B1 (fr) 2006-01-04
AU737552B2 (en) 2001-08-23
US6277872B1 (en) 2001-08-21
HUP0001652A3 (en) 2002-12-28
PL332432A1 (en) 1999-09-13
AR008496A1 (es) 2000-01-19
DE59712543D1 (de) 2006-03-30
ID18613A (id) 1998-04-23
BR9714354A (pt) 2000-04-11
SK49999A3 (en) 1999-11-08
BG103251A (en) 2000-02-29
CA2268954C (fr) 2006-06-13
EP0934288A1 (fr) 1999-08-11
CN1086698C (zh) 2002-06-26
JP2000505089A (ja) 2000-04-25
NO991815D0 (no) 1999-04-16
DE19643037A1 (de) 1998-04-23
YU40997A (sh) 2000-10-30
HRP970553A2 (en) 1998-08-31
NZ335598A (en) 2001-06-29
CZ138099A3 (cs) 1999-11-17
ZA979220B (en) 1998-04-20
ATE315034T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
EE9900147A (et) Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena
FI955235A0 (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
EE04716B1 (et) Diasendatud bitsüklilised heterotsüklid, nende valmistamine ja kasutamine ravimitena
HK1019605A1 (en) Substituted isoquinoline-3-carboxamides, their preparation and their use as pharmaceuticals
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
FI955913A0 (fi) Uudet erytromysiinijohdannaiset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
EE9900018A (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
CY2013003I2 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
EE200000037A (et) Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
EE9800265A (et) Erütromütsiini derivaadid, nende valmistamismeetod ja kasutamine ravimitena
FI103704B1 (fi) Mikrobinvastainen koostumus, sen valmistusmenetelmä ja sen käyttö
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE9800145A (et) Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
AU1504495A (en) Substituted heterocyclic carboxamidoesters, their preparation and their use as pharmaceuticals
EE9900034A (et) Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
EE04398B1 (et) Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiin-10-oolid, nende valmistamise meetod ja kasutamine ravimitena
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
FI941914A (fi) 2-amino-4-kinoliinidihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
FI955679A0 (fi) Piperidiinijohdannaisia, niiden valmistus ja käyttö